Terragen Holdings (ASX:TGH): Microbial Technology Shapes Agricultural Biotechnology Strategy

Sonal Goyal

19 September 2026 12:21 AM AEST

Terragen Holdings (ASX:TGH): Microbial Technology Shapes Agricultural Biotechnology Strategy

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Terragen develops microbial-based agricultural products for animal and soil health.
The company’s products include Mylo and Great Land Plus.
Commercial adoption and Revenue growth remain central development priorities.
Funding, distribution and market acceptance are key considerations.

Terragen Holdings Limited (ASX:TGH) is an Australian agricultural biotechnology company developing microbial-based products designed to support animal and soil health. The company focuses on biological solutions that use beneficial microbes as alternatives within agricultural systems. This article examines Terragen’s technology platform, product portfolio and commercial development pathway.

Microbial technology and agricultural applications

Terragen’s Business is built around the use of live microbial products designed for agricultural applications. The company develops biological solutions intended to support livestock productivity and plant health while providing alternatives to traditional agricultural inputs.

Mylo and Great Land Plus products

Mylo is a microbial feed supplement developed for cattle, while Great Land Plus is a plant bio-stimulant product. These products represent Terragen’s approach to applying microbial technology across different areas of agriculture. Commercial uptake depends on demonstrating value for farmers and agricultural users.

Commercialisation pathway

Terragen has focused on expanding market access through product validation, distribution relationships and customer engagement. Agricultural products often require field-based evidence and practical benefits before achieving broader adoption across farming operations.

Financial and operational considerations

Developing agricultural biotechnology products requires Investment in research, Manufacturing and market development. Terragen continues to manage commercial expansion while working to establish sustainable revenue streams from its product portfolio.

Market opportunities and challenges

Biological agricultural products are being explored as farming practices evolve. However, adoption can vary depending on seasonal conditions, farm requirements and comparison with established agricultural inputs. Building confidence among users remains an important part of commercial growth.

Future milestones

Key areas to monitor include product sales growth, distribution expansion, field trial outcomes and progress towards improving commercial scale. Continued evidence of customer adoption will be important for evaluating the company’s development.

Key Insights

Terragen represents an agricultural biotechnology company applying microbial science to farming challenges. The company’s future progress depends on converting biological product development into repeatable commercial activity through customer adoption, distribution and operational execution.

FAQs

Q: What does Terragen Holdings develop?

A:Terragen develops microbial-based agricultural products.

Q: What is Mylo?

A:Mylo is a microbial feed supplement developed for cattle.

Q: What is Great Land Plus?

A:Great Land Plus is a plant bio-stimulant product.

Q: What markets does Terragen target?

A:The company targets agricultural applications including animal and soil health.

Q: What factors influence Terragen’s progress?

A:Product adoption, distribution, funding and commercial execution are key factors.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.